The title complex（C66H76O8·CH3CN） was synthesized and structurally determined by single-crystal X-ray diffraction method. It crystallizes in monoclinic, space group P21/c with a = 22.384（13）, b = 13.413（7）,...The title complex（C66H76O8·CH3CN） was synthesized and structurally determined by single-crystal X-ray diffraction method. It crystallizes in monoclinic, space group P21/c with a = 22.384（13）, b = 13.413（7）, c = 21.867（12）, β = 112.257（7）°, C68H78NO8, Mr = 1037.31, Dc = 1.133 g/cm3, V = 6076（6） 3, Z = 4, F（000） = 2224, μ（MoKa） = 0.073 mm-1, T = 296（2） K, 10276 independent reflections with 5469 observed ones（I 〉 2σ（I））, R = 0.0797 and wR = 0.2316 with GOF = 1.027（R = 0.1442 and wR = 0.2689 for all data）. The calixarene moiety maintains the symmetric cone conformation through intramolecular O–H···O hydrogen bonds. The inhibition of the strand transfer process of HIV-1 integrase of the title compound was also evaluated. Preliminary bioassays indicated that it has a low inhibition ratio（24.85%） at the concentration of 50 μM.展开更多
基金supported by the National Natural Science Foundation of China(No.21102003)National Students'Innovation and Entrepreneurship Training Program(No.201210361094)+1 种基金Scientific Research Foundation for the Introduction of TalentYoung Teachers Scientific Research Foundation of Anhui University of Science&Technology(11214,2012QNY27)
文摘The title complex（C66H76O8·CH3CN） was synthesized and structurally determined by single-crystal X-ray diffraction method. It crystallizes in monoclinic, space group P21/c with a = 22.384（13）, b = 13.413（7）, c = 21.867（12）, β = 112.257（7）°, C68H78NO8, Mr = 1037.31, Dc = 1.133 g/cm3, V = 6076（6） 3, Z = 4, F（000） = 2224, μ（MoKa） = 0.073 mm-1, T = 296（2） K, 10276 independent reflections with 5469 observed ones（I 〉 2σ（I））, R = 0.0797 and wR = 0.2316 with GOF = 1.027（R = 0.1442 and wR = 0.2689 for all data）. The calixarene moiety maintains the symmetric cone conformation through intramolecular O–H···O hydrogen bonds. The inhibition of the strand transfer process of HIV-1 integrase of the title compound was also evaluated. Preliminary bioassays indicated that it has a low inhibition ratio（24.85%） at the concentration of 50 μM.
